Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03691454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma

Study acronym: RESOLVE-2
StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 21, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 31 days later Aug 30, 2026 → Sep 30, 2026
See other at-risk trials from Peking University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 30, 2026 to Sep 30, 2026
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints revised (2)
  2. Primary completion date: Jun 30, 2022 to Aug 30, 2026v2 Show 7 more changesShow less
    • Enrollment target: 258 to 248
    • Study completion date: Jun 30, 2023 to Jun 30, 2027
    • Interventions: Docetaxel (Drug), Oxaliplatin (Drug) to Docetaxel+Oxaliplatin+S-1+Toripalimab (Drug), Oxaliplatin+S-1+Toripalimab (Drug)
    • Eligibility criteria expanded, about 153 words
    • Secondary endpoints revised (2)
    • Study description expanded, about 48 words
    • Study title expanded, about 4 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Peking University
118 trials monitored
See 4 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
This is a randomized, multicenter, controlled, adaptive phase II/III clinical study. The aim is to compare neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) plus toripalimab versus oxaliplatin and S-1 (SOX) plus toripalimab in patients with locally advanced gastric adenocarcinoma.
Trial Details
NCT Number NCT03691454
Lead Sponsor Peking University
Conditions
(from sponsor)		 Gastric Adenocarcinoma
Enrollment 248 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov